Trial Profile
Expanded Access With Trappsol Cyclo for an Individual Patient With Late Onset Alzheimer's Disease
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 25 May 2021
Price :
$35
*
At a glance
- Drugs Hydroxypropyl betadex (Primary)
- Indications Alzheimer's disease
- Focus Expanded access; Therapeutic Use
- Sponsors CTD Holdings; Cyclo Therapeutics
- 20 May 2021 According to a Cyclo Therapeutics media release, based on data from this trial the company is planning an early phase clinical trial using Trappsol Cyclo intravenously in Alzheimer's Disease.
- 17 Jun 2020 18 months results presented in the Cyclo Therapeutics Media Release.
- 13 Aug 2019 Results presented in a CTD Holdings media release.